Takeda Pharmaceutical Company Limited (TAK) — Financial statements
Income statement, balance sheet, and cash flow for Takeda Pharmaceutical Company Limited — annual and quarterly history with growth and margin analysis.
| Metric (JPY Millions) | 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 4,777,450↑4.3% | 4,581,551↑7.5% | 4,263,762↑5.9% | 4,027,478↑12.8% | 3,569,006 | |
| Cost of Revenue | 2,338,119↑48.0% | 1,580,217↑10.4% | 1,431,505↑15.1% | 1,244,072↑12.4% | 1,106,846 | |
| Gross Profit | 2,439,332↓18.7% | 3,001,334↑6.0% | 2,832,257↑1.8% | 2,783,406↑13.0% | 2,462,160 | |
| Operating Expenses | ||||||
| R&D Expenses | 716,688↓1.9% | 730,227↑0.0% | 729,924↑15.3% | 633,325↑20.4% | 526,087 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 1,149,602↑4.1% | 1,104,766↑4.8% | 1,053,819↑5.7% | 997,309↑12.5% | 886,361 | |
| Other Expenses | 0.00↓100.0% | 823,755↓1.3% | 834,439↑26.0% | 662,267↑12.5% | 588,867 | |
| Operating Expenses | 1,866,289↓29.8% | 2,658,748↑1.5% | 2,618,182↑14.2% | 2,292,900↑14.6% | 2,001,315 | |
| Total Costs & Expenses | 4,204,408↓0.8% | 4,238,965↑4.7% | 4,049,687↑14.5% | 3,536,972↑13.8% | 3,108,161 | |
| Operating Results | ||||||
| Operating Income | 573,042↑67.3% | 342,586↑60.0% | 214,075↓56.4% | 490,505↑6.4% | 460,844 | |
| Depreciation & Amortization | 764,617↑0.4% | 761,396↑18.1% | 644,461↓3.0% | 664,400↑13.9% | 583,151 | |
| EBITDA | 1,337,659↑10.5% | 1,210,512↑5.8% | 1,143,936↓10.9% | 1,284,067↑8.5% | 1,183,213 | |
| EBIT | 573,042↑27.6% | 449,116↓10.1% | 499,475↓19.4% | 619,667↑3.3% | 600,062 | |
| Interest & Other Income | ||||||
| Net Interest Income | -155,224↓31.9% | -117,673↓11854.5% | -984↑99.1% | -111,192↑5.5% | -117,669 | |
| Interest Income | 223,913↑1040.2% | 19,638↑25045.7% | 78↓98.6% | 5,508↑20.0% | 4,591 | |
| Interest Expense | 379,136↑176.1% | 137,311↑12824.1% | 1,062↓99.1% | 116,973↓4.5% | 122,432 | |
| Non-Operating Income | 0.00↑100.0% | -106,530↑62.7% | -285,400↓121.0% | -129,162↑7.2% | -139,218 | |
| Other Income / Expenses | -297,162↓77.4% | -167,502↓3.9% | -161,284↓39.7% | -115,415↑27.1% | -158,273 | |
| Income Before Tax | 275,880↑57.6% | 175,084↑231.7% | 52,791↓85.9% | 375,090↑24.0% | 302,571 | |
| Income Tax Expense | 72,274↑8.0% | 66,941↑173.2% | -91,406↓257.5% | 58,052↓19.8% | 72,405 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 203,607↑88.3% | 108,143↓25.0% | 144,197↓54.5% | 317,038↑37.7% | 230,166 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 203,327↑88.4% | 107,928↓25.1% | 144,067↓54.6% | 317,017↑37.8% | 230,059 | |
| Bottom-Line Net Income | 203,327↑88.4% | 107,928↓25.1% | 144,067↓54.6% | 317,017↑37.8% | 230,059 | |
| EPS (Basic) | 63.91↑87.0% | 34.17↓25.8% | 46.05↓54.9% | 102.15↑38.8% | 73.57 | |
| EPS (Diluted) | 63.91↑90.1% | 33.62↓26.2% | 45.58↓54.9% | 100.97↑38.4% | 72.94 | |
| Weighted Average Shares | 3,150↓1.9% | 3,211↑2.6% | 3,129↑0.8% | 3,104↓0.7% | 3,127 | |
| Weighted Average Diluted Shares | 3,206↓0.2% | 3,211↑1.6% | 3,161↑0.7% | 3,140↓0.5% | 3,154 | |
* All figures in Millions of JPY, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.